THE PECULIARITIES OF MUCOCILIARY SYSTEM FUNCTIONING IN PATIENTS WITH BRONCHIAL ASTHMA AT ZAFIRLUKAST TREATMENT
The study comprised 92 patients with bronchial asthma, with 85% of them having mucociliary insufficiency the intensity of which was in direct proportion to the severity of the disease and the activity of inflammatory process in airways. The severity of mucociliary insufficiency is diagnosed through the intensity of morphological changes in the bronchi mucosa and the disturbance of ciliated epithelium ciliary mechanism structure, the drop of ciliated epithelium ciliary activity. Zafirlukast is a pathogenetically proved effective medication for mucociliary insufficiency correction in patients with bronchial asthma. The use of zafirlukast in a standard dose during 12 weeks leads to the decrease of functional manifestations of mucociliary insufficiency. The correcting zafirlukast effect upon mucociliary insufficiency can be prognosticated by initial data of mucociliary clearance speed or by closely connected parameters of inflammation activity, cilia beat frequency and ciliated epithelium cilia length, the height of bronchi epithelium and the thickness of the basic membrane with discriminant equations solving.